Comparative analysis was performed at both nucleic acid and protein vaccine levels to provides a reference for the "glycosylation quality control" of SARS-CoV-2 RBD vaccines. For instance, monitoring the glycoform distribution at the N343 site (e.g., ensuring the proportion of the M5 glycoform is ≥30%) can help maintain the structural stability of the vaccine antigen and the consistency of its immunogenicity. Additionally, the findings regarding the characterization of various glycosylation sites can offer a solution to the longstanding challenge of difficult horizontal comparison among different recombinant SARSCoV- 2 RBD protein vaccines.